In this presentation from The Intellectual Investor Conference, Jason Wallace of Top Mark Health Partners lays out the investment case around minimal residual disease (MRD) testing — the blood-based technology that detects tumor DNA shed into the bloodstream, catching cancer recurrence months earlier than a scan and at extraordinarily low concentrations. Wallace frames MRD as a shift in cancer care from episodic rescue to proactive surveillance, and argues the addressable market is far larger than most models assume — potentially tens of millions of blood draws per year at full adoption. He walks through the structure of the field (blood versus solid tumor, tumor-informed versus fixed-panel approaches), the state of the evidence (strong prognostic signal, but clinical utility still being proven in trials like DYNAMIC-III), and the reimbursement backdrop, where Medicare is moving ahead of commercial payers and coverage is currently the key competitive moat. He also highlights personalized cancer vaccines as a second demand catalyst, since they rely on MRD as both trigger and readout.
Rather than trying to pick the winning assay in a crowded, unsettled field of test developers, Wallace makes a “picks and shovels” argument: every test, regardless of brand, ultimately runs on the same underlying inputs — sequencers, custom panels, and reagents. His tier-1 pick is Illumina, the near-ubiquitous sequencing substrate beneath most clinical MRD tests, which he contends has traded at depressed levels due to the Grail acquisition saga and a biotech funding freeze even as the underlying MRD wave builds and its customer base tips from research toward the far larger clinical market. The thesis, in short: own the durable infrastructure rather than the individual assay. Download the full deck below to explore the market sizing, competitive map, and earnings drivers in detail.
Presentation summary generated by AI